Bringing the Oncology Community Together

Dr. Mateos on Elderly Patients With Newly Diagnosed MM

María-Victoria Mateos
Published Online: Monday, December 16, 2013
María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

In the GEM2010MAS65 trial, researchers conducted a comparison of sequential and alternating administration of bortezomib, melphalan, and prednisone and lenalidomide plus dexamethasone in elderly patients with newly diagnosed multiple myeloma.

The combination of melphalan, bortezomib, lenalidomide, and steroids in this patient population in a sequential or alternating scheme is feasible, Mateos says. In terms of complete remission, the alternating scheme showed superior efficacy, though a longer follow-up is needed.

Related Articles
Treatment of MDS Refractory to Hypomethylating Agent
Panelists discuss the limited number of treatment options that exist for patients with myelodysplastic syndromes who progress on hypomethylating agents, such as azacitidine and decitabine.
New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.